Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer

Triple-negative breast cancers have unfavorable outcomes due to their inherent aggressive behavior and lack of targeted therapies. Breast cancers occurring in BRCA1 mutation carriers are mostly triple-negative and harbor homologous recombination deficiency, sensitizing them to inhibition of a second...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Med Oncol
Egile Nagusiak: Heerma van Voss, Marise R., Brilliant, Justin D., Vesuna, Farhad, Bol, Guus M., van der Wall, Elsken, van Diest, Paul J., Raman, Venu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5576028/
https://ncbi.nlm.nih.gov/pubmed/28138868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-017-0889-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak